Matt O'Brien
Stock Analyst at Piper Sandler
(2.17)
# 2,605
Out of 4,826 analysts
174
Total ratings
40.54%
Success rate
-7.28%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Maintains: Overweight | $100 → $90 | $80.25 | +12.15% | 11 | May 2, 2025 | |
| ATEC Alphatec Holdings | Reiterates: Overweight | $13 → $15 | $11.98 | +25.21% | 3 | May 2, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Overweight | $36 → $30 | $21.33 | +40.65% | 8 | May 1, 2025 | |
| TMDX TransMedics Group | Reiterates: Overweight | $90 → $105 | $92.21 | +13.87% | 10 | Apr 29, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $180 → $165 | $86.86 | +89.96% | 10 | Apr 15, 2025 | |
| KMTS Kestra Medical Technologies | Initiates: Overweight | $27 | $22.47 | +20.16% | 1 | Mar 31, 2025 | |
| TELA TELA Bio | Downgrades: Neutral | $5 → $2 | $0.99 | +102.02% | 6 | Mar 21, 2025 | |
| SGHT Sight Sciences | Maintains: Neutral | $5.5 → $3.5 | $2.93 | +19.45% | 7 | Mar 6, 2025 | |
| TFX Teleflex | Downgrades: Neutral | $255 → $140 | $122.86 | +13.95% | 5 | Feb 28, 2025 | |
| BBNX Beta Bionics | Initiates: Overweight | $26 | $11.80 | +120.34% | 1 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $310 | $258.83 | +19.77% | 8 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $250 → $330 | $294.17 | +12.18% | 13 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $29.15 | +71.53% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $16 | $18.98 | -15.70% | 7 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $20 | $7.79 | +156.74% | 8 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $115 | $104.24 | +10.32% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 → $12 | $9.19 | +30.58% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $100 | $70.49 | +41.86% | 11 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $380 → $420 | $381.56 | +10.07% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $125 → $140 | $116.48 | +20.19% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $75 | $54.41 | +37.84% | 3 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $90 | $83.35 | +7.98% | 9 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $80 | $56.92 | +40.55% | 12 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $14.32 | +74.64% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $40 | $21.26 | +88.19% | 1 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $1.26 | +138.10% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $1.17 | +284.62% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $90.48 | - | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $2.55 | +489.39% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $81.61 | +33.26% | 1 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $18 | $2.11 | +763.66% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $30.43 | +162.90% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $2.76 | +334.78% | 1 | Jun 24, 2020 |
DexCom
May 2, 2025
Maintains: Overweight
Price Target: $100 → $90
Current: $80.25
Upside: +12.15%
Alphatec Holdings
May 2, 2025
Reiterates: Overweight
Price Target: $13 → $15
Current: $11.98
Upside: +25.21%
Tandem Diabetes Care
May 1, 2025
Maintains: Overweight
Price Target: $36 → $30
Current: $21.33
Upside: +40.65%
TransMedics Group
Apr 29, 2025
Reiterates: Overweight
Price Target: $90 → $105
Current: $92.21
Upside: +13.87%
Glaukos
Apr 15, 2025
Maintains: Overweight
Price Target: $180 → $165
Current: $86.86
Upside: +89.96%
Kestra Medical Technologies
Mar 31, 2025
Initiates: Overweight
Price Target: $27
Current: $22.47
Upside: +20.16%
TELA Bio
Mar 21, 2025
Downgrades: Neutral
Price Target: $5 → $2
Current: $0.99
Upside: +102.02%
Sight Sciences
Mar 6, 2025
Maintains: Neutral
Price Target: $5.5 → $3.5
Current: $2.93
Upside: +19.45%
Teleflex
Feb 28, 2025
Downgrades: Neutral
Price Target: $255 → $140
Current: $122.86
Upside: +13.95%
Beta Bionics
Feb 24, 2025
Initiates: Overweight
Price Target: $26
Current: $11.80
Upside: +120.34%
Feb 21, 2025
Maintains: Overweight
Price Target: $285 → $310
Current: $258.83
Upside: +19.77%
Feb 19, 2025
Reiterates: Overweight
Price Target: $250 → $330
Current: $294.17
Upside: +12.18%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $50
Current: $29.15
Upside: +71.53%
Feb 12, 2025
Maintains: Neutral
Price Target: $40 → $16
Current: $18.98
Upside: -15.70%
Feb 5, 2025
Maintains: Overweight
Price Target: $16 → $20
Current: $7.79
Upside: +156.74%
Feb 3, 2025
Maintains: Overweight
Price Target: $95 → $115
Current: $104.24
Upside: +10.32%
Nov 8, 2024
Reiterates: Neutral
Price Target: $9 → $12
Current: $9.19
Upside: +30.58%
Nov 6, 2024
Maintains: Overweight
Price Target: $80 → $100
Current: $70.49
Upside: +41.86%
Oct 30, 2024
Reiterates: Overweight
Price Target: $380 → $420
Current: $381.56
Upside: +10.07%
Oct 25, 2024
Reiterates: Overweight
Price Target: $125 → $140
Current: $116.48
Upside: +20.19%
Oct 8, 2024
Reiterates: Overweight
Price Target: $75
Current: $54.41
Upside: +37.84%
Aug 21, 2024
Maintains: Neutral
Price Target: $85 → $90
Current: $83.35
Upside: +7.98%
Aug 1, 2024
Maintains: Overweight
Price Target: $95 → $80
Current: $56.92
Upside: +40.55%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $14.32
Upside: +74.64%
Mar 27, 2024
Reiterates: Overweight
Price Target: $40
Current: $21.26
Upside: +88.19%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $1.26
Upside: +138.10%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $1.17
Upside: +284.62%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $90.48
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $2.55
Upside: +489.39%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $81.61
Upside: +33.26%
Jan 29, 2021
Downgrades: Neutral
Price Target: $25 → $18
Current: $2.11
Upside: +763.66%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $30.43
Upside: +162.90%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $2.76
Upside: +334.78%